Wall Street analysts expect Neuronetics Inc (NASDAQ:STIM) to announce earnings of ($0.43) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Neuronetics’ earnings. Neuronetics reported earnings per share of ($30.60) during the same quarter last year, which would suggest a positive year-over-year growth rate of 98.6%. The company is expected to issue its next earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Neuronetics will report full-year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.62). For the next financial year, analysts expect that the company will post earnings of ($1.58) per share, with EPS estimates ranging from ($1.74) to ($1.41). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Neuronetics.
Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). Neuronetics had a negative return on equity of 1,385.60% and a negative net margin of 47.21%. The business had revenue of $12.73 million for the quarter, compared to analysts’ expectations of $12.72 million.
Shares of Neuronetics stock traded up $0.04 during trading hours on Friday, reaching $12.55. 2,645 shares of the company’s stock were exchanged, compared to its average volume of 164,120. Neuronetics has a 52-week low of $8.90 and a 52-week high of $39.39. The company has a market capitalization of $229.04 million and a price-to-earnings ratio of -4.65. The company’s fifty day moving average is $12.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 8.94 and a quick ratio of 8.74.
In other Neuronetics news, insider Daniel Guthrie sold 3,685 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Peter Donato sold 8,595 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $14.93, for a total transaction of $128,323.35. The disclosure for this sale can be found here. Insiders sold 50,333 shares of company stock worth $786,186 in the last three months. 12.00% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Neuronetics by 49.9% during the fourth quarter. BlackRock Inc. now owns 612,423 shares of the company’s stock valued at $11,851,000 after buying an additional 203,983 shares during the period. Lord Abbett & CO. LLC increased its holdings in Neuronetics by 2.5% in the 4th quarter. Lord Abbett & CO. LLC now owns 428,007 shares of the company’s stock worth $8,282,000 after buying an additional 10,414 shares in the last quarter. Cortina Asset Management LLC increased its holdings in Neuronetics by 25.7% in the 2nd quarter. Cortina Asset Management LLC now owns 380,717 shares of the company’s stock worth $4,763,000 after buying an additional 77,949 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in Neuronetics by 23.5% in the 1st quarter. Wasatch Advisors Inc. now owns 313,954 shares of the company’s stock worth $4,788,000 after buying an additional 59,740 shares in the last quarter. Finally, Pier Capital LLC grew its stake in shares of Neuronetics by 12.8% during the 1st quarter. Pier Capital LLC now owns 310,375 shares of the company’s stock valued at $4,733,000 after purchasing an additional 35,339 shares during the period. Institutional investors own 80.61% of the company’s stock.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Further Reading: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.